Danielle Antalffy
Stock Analyst at UBS
(3.39)
# 829
Out of 4,814 analysts
161
Total ratings
45.79%
Success rate
2.05%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Downgrades: Neutral | $45 → $16 | $14.44 | +10.80% | 3 | Apr 9, 2025 | |
| MDT Medtronic | Maintains: Neutral | $85 → $95 | $82.70 | +14.87% | 8 | Feb 19, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $105 → $130 | $95.25 | +36.48% | 12 | Feb 7, 2025 | |
| SGHT Sight Sciences | Maintains: Buy | $5.5 → $5 | $2.69 | +85.87% | 2 | Jan 27, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $146 → $148 | $129.70 | +14.11% | 12 | Jan 23, 2025 | |
| GKOS Glaukos | Initiates: Buy | $182 | $90.07 | +102.07% | 1 | Dec 6, 2024 | |
| SYK Stryker | Maintains: Neutral | $366 → $370 | $346.60 | +6.75% | 6 | Oct 30, 2024 | |
| ATRC AtriCure | Maintains: Buy | $35 → $40 | $31.65 | +26.38% | 12 | Oct 30, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $90 → $75 | $71.56 | +4.81% | 12 | Sep 10, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $112 → $107 | $97.88 | +9.32% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $7 | $6.46 | +8.36% | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $163 → $95 | $68.61 | +38.46% | 8 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $26 | $14.92 | +74.26% | 3 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $31.89 | +135.18% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $157.44 | +14.33% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $150.00 | +114.67% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $2.34 | -3.64% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $28.89 | +48.84% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $482.40 | -42.37% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $16.86 | +166.98% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $246.95 | +13.38% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $11.06 | +7,359.31% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $15.56 | -10.03% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $101.32 | -1.30% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $10.80 | +11.11% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $53.04 | -43.44% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $41.19 | +9.26% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $200.40 | +37.23% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $4.21 | +375.06% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.88 | +510.47% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.61 | +392.77% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.03 | +1,356.31% | 1 | Sep 1, 2020 |
RxSight
Apr 9, 2025
Downgrades: Neutral
Price Target: $45 → $16
Current: $14.44
Upside: +10.80%
Medtronic
Feb 19, 2025
Maintains: Neutral
Price Target: $85 → $95
Current: $82.70
Upside: +14.87%
Boston Scientific
Feb 7, 2025
Maintains: Buy
Price Target: $105 → $130
Current: $95.25
Upside: +36.48%
Sight Sciences
Jan 27, 2025
Maintains: Buy
Price Target: $5.5 → $5
Current: $2.69
Upside: +85.87%
Abbott Laboratories
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $129.70
Upside: +14.11%
Glaukos
Dec 6, 2024
Initiates: Buy
Price Target: $182
Current: $90.07
Upside: +102.07%
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $346.60
Upside: +6.75%
AtriCure
Oct 30, 2024
Maintains: Buy
Price Target: $35 → $40
Current: $31.65
Upside: +26.38%
Edwards Lifesciences
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $71.56
Upside: +4.81%
Zimmer Biomet Holdings
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $97.88
Upside: +9.32%
Aug 7, 2024
Maintains: Neutral
Price Target: $6.5 → $7
Current: $6.46
Upside: +8.36%
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $68.61
Upside: +38.46%
Feb 14, 2024
Maintains: Neutral
Price Target: $24 → $26
Current: $14.92
Upside: +74.26%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $31.89
Upside: +135.18%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $157.44
Upside: +14.33%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $150.00
Upside: +114.67%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $2.34
Upside: -3.64%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $28.89
Upside: +48.84%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $482.40
Upside: -42.37%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $16.86
Upside: +166.98%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $246.95
Upside: +13.38%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $11.06
Upside: +7,359.31%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $15.56
Upside: -10.03%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $101.32
Upside: -1.30%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $10.80
Upside: +11.11%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $53.04
Upside: -43.44%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $41.19
Upside: +9.26%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $200.40
Upside: +37.23%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $4.21
Upside: +375.06%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.88
Upside: +510.47%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.61
Upside: +392.77%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $1.03
Upside: +1,356.31%